In a different translational study of AZD4547, 341 patients were screened with fluorescence in situ hybridization; FGFR1 amplification was found in 18% of advanced HER2-negative breast cancers and 9% of advanced gastroesophageal cancers46. Here, ERBB2 is linked to breast carcinoma.